NUTEX Investments Public Limited Company

BUSE:NUTEX Stock Report

Market Cap: Ft3.3b

NUTEX Investments Past Earnings Performance

Past criteria checks 4/6

NUTEX Investments has been growing earnings at an average annual rate of 76.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 0% per year. NUTEX Investments's return on equity is 8.1%, and it has net margins of 103075.6%.

Key information

76.4%

Earnings growth rate

71.6%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate0%
Return on equity8.1%
Net Margin103,075.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

NUTEX Investments' (BUSE:NUTEX) Profits May Be Overstating Its True Earnings Potential

Oct 04
NUTEX Investments' (BUSE:NUTEX) Profits May Be Overstating Its True Earnings Potential

Recent updates

NUTEX Investments' (BUSE:NUTEX) Profits May Be Overstating Its True Earnings Potential

Oct 04
NUTEX Investments' (BUSE:NUTEX) Profits May Be Overstating Its True Earnings Potential

Revenue & Expenses Breakdown

How NUTEX Investments makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BUSE:NUTEX Revenue, expenses and earnings (HUF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240464190
31 Mar 240317200
31 Dec 230171210
30 Sep 230121210
30 Jun 23071210
31 Mar 230101190
31 Dec 220131160
30 Sep 220115150
30 Jun 22099140
31 Mar 22056140
31 Dec 21013130
30 Sep 210-10140
30 Jun 210-32140
31 Mar 210-3160
31 Dec 20026190
30 Sep 20015180
30 Jun 2004180
31 Mar 200-2140
31 Dec 191-8100

Quality Earnings: NUTEX has a high level of non-cash earnings.

Growing Profit Margin: NUTEX's current net profit margins are higher than last year .


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NUTEX's earnings have grown significantly by 76.4% per year over the past 5 years.

Accelerating Growth: NUTEX's earnings growth over the past year (556.1%) exceeds its 5-year average (76.4% per year).

Earnings vs Industry: NUTEX earnings growth over the past year (556.1%) exceeded the Pharmaceuticals industry 9.5%.


Return on Equity

High ROE: NUTEX's Return on Equity (8.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 04:02
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NUTEX Investments Public Limited Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution